Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer

Fig. 6

Schematic illustration of the mechanism by which IPD enhances immunotherapy response. Th2-mediated immunity suppresses ICB response by inhibiting the infiltration and cytotoxic activity of CD8+ T cell and reshaping the global immune landscape including decreasing the infiltration of effector CD4+ T cell and recruiting immunosuppressive cells such as MDSCs and M2-macrophage in tumor microenvironment. Targeting Th2 immunity by IPD can reverse the immunosuppressive microenvironment, thereby improve ICB response and inhibit tumor growth of breast cancer

Back to article page